Patents by Inventor Richard R. Spaete

Richard R. Spaete has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Large capacity viral amplicon using a minimal orilyt from human cytomegalovirus
    Patent number: 7589071
    Abstract: A novel Human Cytomegalovirus vector system is provided. The vector system is characterized by an amplicon vector, having an HCMV derived origin and cleavage packaging signal, and a helper virus function. The vector system is capable of infecting a wide range of host cells, including human CD34+ hematopoietic progenitor cells. Methods, including therapeutic and prophylactic methods, for introducing heterologous polynucleotide sequences into cells using the vector system are also provided.
    Type: Grant
    Filed: June 19, 2002
    Date of Patent: September 15, 2009
    Assignee: MedImmune, LLC
    Inventors: Richard R. Spaete, George Kemble
  • Methods and compositions for controlling translation of HCV proteins
    Patent number: 7018984
    Abstract: Embodiments of the present invention feature methods and compositions for controlling the translation of viral peptides and proteins from viral nucleic acid, with particular applications to pestivirus and HCV. The methods and compositions feature control elements of the 5?UT region of the viral genome.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: March 28, 2006
    Assignee: Chiron Corporation
    Inventors: Jang H. Han, Richard R. Spaete, Byoung J. Yoo, Byung S. Suh, Mark J. Selby, Michael Houghton
  • Method to detect CMV by hybridization with a gp55 specific DNA probe
    Patent number: 6190860
    Abstract: The present invention provides recombinant polypeptides derived from CMV glycoprotein gB and truncated fragments thereof which contain at least one epitope which is immunologically identifiable with one encoded by the CMV genome. The complete characterization of the gB protein, including the identity of glycoprotein gp55, permits the production of polypeptides which are useful as standards or reagents in diagnostic tests and/or as components of vaccines. This invention provides recombinant polypeptides and recombinant polynucleotides encoding these polypeptides wherein a neutralizing epitope of gB is localized within gp55.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: February 20, 2001
    Assignee: Chiron Corporation
    Inventors: Richard R. Spaete, Carol A. Pachl
  • Methods and compositions for controlling translation of HCV proteins
    Patent number: 6057093
    Abstract: Embodiments of the present invention feature methods and compositions for controlling the translation of viral peptides and proteins from viral nucleic acid, with particular applications to pestivirus and HCV. The methods and compositions feature control elements of the 5'UT region of the viral genome.
    Type: Grant
    Filed: May 12, 1995
    Date of Patent: May 2, 2000
    Assignee: Chiron Corporation
    Inventors: Jang H. Han, Richard R. Spaete, Byoung J. Yoo, Byung S. Suh, Mark J. Selby, Michael Houghton
  • Methods and compositions for controlling translation of HCV proteins
    Patent number: 5922857
    Abstract: Embodiments of the present invention feature methods and compositions for controlling the translation of viral peptides and proteins from viral nucleic acid, with particular applications to pestiviras and HCV. The methods and compositions feature control elements of the 5'UT region of the viral genome.
    Type: Grant
    Filed: May 12, 1995
    Date of Patent: July 13, 1999
    Assignee: Chiron Corporation
    Inventors: Jang H. Han, Richard R. Spaete, Byoung J. Yoo, Byung S. Suh, Mark J. Selby, Michael Houghton
  • Polynucleotides encoding CMV neutralizing proteins
    Patent number: 5834307
    Abstract: The present invention provides recombinant polypeptides derived from CMV glycoprotein gB and truncated fragments thereof which contain at least one epitope which is immunologically identifiable with one encoded by the CMV genome. The complete characterization of the gB protein, including the identity of glycoprotein gp55, permits the production of polypeptides which are useful as standards or reagents in diagnostic tests and/or as components of vaccines. This invention provides recombinant polypeptides and recombinant polynucleotides encoding these polypeptides wherein a neutralizing epitope of gB is localized within gp55.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: November 10, 1998
    Assignee: Chiron Corporation
    Inventors: Richard R. Spaete, Carol A. Pachl
  • Recombinant CMV neutralizing proteins
    Patent number: 5547834
    Abstract: The present invention provides recombinant polypeptides derived from CMV glycoprotein gB and truncated fragments thereof which contain at least one epitope which is immunologically identifiable with one encoded by the CMV genome. The complete characterization of the gB protein, including the identity of glycoprotein gp55, permits the production of polypeptides which are useful as standards or reagents in diagnostic tests and/or as components of vaccines. This invention provides recombinant polypeptides and recombinant polynucleotides encoding these polypeptides wherein a neutralizing epitope of gB is localized within gp55.
    Type: Grant
    Filed: November 15, 1994
    Date of Patent: August 20, 1996
    Assignee: Chiron Corporation
    Inventors: Richard R. Spaete, Carol A. Pachl